Previous 10 | Next 10 |
Gainers: Novavax (NVAX) +259%. Precision BioSciences (DTIL) +114%. Amazon.com (AMZN) +39%. Adobe (ADBE) +32%. Paratek Pharmaceuticals (PRTK) +15%. Losers:Euronet Worldwide (EEFT) -5%. Seres Therapeutics (MCRB) -5%. Sanderson Farms (SAFM) -5%. Morphic Holding (MORF) -4%. Redbox Entertainm...
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Bruce Rogers, Ph.D., President of Morphic, will gi...
WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Joanne Gibbons has been named Senior Vice Presi...
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will participate in ...
WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced two key executive appointments. Dr. Bruce Rogers has...
Morphic press release (NASDAQ:MORF): Q1 GAAP EPS of -$0.85 misses by $0.04. Revenue of $2.38M (-27.0% Y/Y) misses by $0.84M. Shares -1.06% PM. For further details see: Morphic GAAP EPS of -$0.85 misses by $0.04, revenue of $2.38M misses by $0.84M
Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Described new understanding of α4β7-expressing immune cells and MORF-057 dose response in oral presentation at ECCO 2022 Announced key appointments and advancements in leadersh...
Shares of Morphic Holding (NASDAQ:MORF) are up 7% in Tuesday afternoon trading on volume more than 5 times its normal daily average. As of 342p ET, more than 1.4M shares had traded hands. On a normal day, volume is ~264K. The oral small-molecule integrin therapeutics developer has o...
Gainers: Evoke Pharma (EVOK) +151%. Avadel Pharmaceuticals (AVDL) +26%. Arch Resources (ARCH) +21%. Magnachip Semiconductor (MX) +20%. TradeUP Global (TUGCU) +20%. Jiuzi Holdings (JZXN) +19%. Forge Global Holdings (FRGE) +18%. Morphic Holding (MORF) +16%. Flexsteel Industries (FLXS) +15%. Sky...
Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leader Aaron Pelta promoted to Senior Vice President, Business and Corporate Development; leading portfolio, commercial, and partnering strategy WALTHAM, Mass., April 06, ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 08:15:05 ET RBC Capital analyst issues SECTOR PERFORM recommendation for MORF on July 9, 2024 06:29AM ET. The previous analyst recommendation was Outperform. MORF was trading at $55.74 at issue of the analyst recommendation. The overall analyst consensus : BUY...
2024-07-08 20:00:07 ET Edward Nash from Canaccord Genuity issued a price target of $57.00 for MORF on 2024-07-08 18:49:00. The adjusted price target was set to $57.00. At the time of the announcement, MORF was trading at $55.74. The overall price target consensus is at $...